Rating Change
Goldman Sachs analysts reiterated a Buy rating on Relay Therapeutics, Inc. (NASDAQ:RLAY) on July 21, 2026.
reiterateNASDAQ:RLAY
Goldman Sachs Reiterates Buy Rating on Relay Therapeutics, Inc. (RLAY)
Rating Change Goldman Sachs analysts reiterated a Buy rating on Relay Therapeutics, Inc. (NASDAQ:RLAY) on July 21, 2026. Market Context Relay Therapeutics, Inc.
Market Context
Relay Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $19.79 with a market capitalization of $1.4B.
Analyst coverage from Goldman Sachs provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Relay Therapeutics, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Relay Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 21, 2026 | Goldman Sachs | Buy | N/A |
| Jul 16, 2026 | Canaccord Genuity | Buy | N/A |
| Jul 08, 2026 | JP Morgan | Overweight | N/A |
| May 26, 2026 | Guggenheim | Buy | N/A |
| May 26, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View RLAY Stock Page
Frequently Asked Questions
What does a Buy rating mean for RLAY?
A Buy rating from Goldman Sachs reflects the analyst's outlook on Relay Therapeutics, Inc. (NASDAQ:RLAY). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the RLAY forecast page.